SLDB Stock Summary and Trading Ideas (Solid Biosciences | NASDAQ:SLDB)

Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.

Solid Biosciences trades on the NASDAQ stock market under the symbol SLDB.

As of March 27, 2026, SLDB stock price declined to $7.11 with 808,460 million shares trading.

SLDB has a beta of 1.98, meaning it tends to be more sensitive to market movements. SLDB has a correlation of 0.12 to the broad based SPY ETF.

SLDB has a market cap of $699.56 million. This is considered a Small Cap stock.

In the last 3 years, SLDB traded as high as $15.05 and as low as $1.81.

The top ETF exchange traded funds that SLDB belongs to (by Net Assets): VTI, IWM, IWN, IBB, VXF.

SLDB has outperformed the market in the last year with a price return of +62.7% while the SPY ETF gained +13.1%. SLDB has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +21.7% and -2.7%, respectively, while the SPY returned -7.9% and -4.0%, respectively.

SLDB support price is $7.17 and resistance is $8.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLDB shares will trade within this expected range on the day.